- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00132925
An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis
An Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD Children Ages 2-5 Years With Perennial Allergic Rhinitis
The purposes of this study are:
- To demonstrate the efficacy of once daily administration of Nasacort AQ 110 µg compared with placebo in children 2-5 years of age with perennial allergic rhinitis; and
- To assess the safety of Nasacort AQ 110 µg in children 2-5 years of age.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New Jersey
-
Bridgewater, New Jersey, United States, 08807
- Sanofi-Aventis, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects will be male or female children ages 2-5 years with a history of at least 1 year of perennial allergic rhinitis (PAR) with or without seasonal allergic rhinitis (SAR) characterized by nasal stuffiness, nasal discharge, sneezing, nasal itching, and total eye symptoms, and verified by positive skin test or radioallergosorbent test (RAST) to perennial allergen that is present in the subject's environment (documented historical testing performed during the past year will be accepted).
- Subjects (assisted by a parent/guardian/care provider) must meet an aggregate symptom score of at least 18 (out of a possible 36) for nasal stuffiness, nasal discharge and sneezing for both the reflective (previous 24 hours) and instantaneous symptom scores recorded in the morning
- Subjects must not have clinically relevant disease other than allergic rhinitis or have clinically relevant deviations from normal on a physical examination.
- Subjects must not have been recently exposed to rhinitis medications prior to screening
- Subjects must have no history of hypersensitivity to glucocorticoids or to any excipients of the formulation
- Subjects undergoing cosyntropin stimulation test must have a morning (8 AM ± 1 hour) pre-stimulation serum cortisol level ≥ 5 µg/dL and 30 minutes post-stimulation serum cortisol level ≥ 18 µg/dL at screening
Exclusion Criteria:
Subjects presenting with any of the following will not be included in the study:
- Asthma, requiring chronic use of inhaled or systemic corticosteroids in the previous 6 months; upper respiratory tract infection or sinus infection requiring antibiotic therapy within 2 weeks prior to screening or viral upper respiratory tract infection within 7 days of screening.
- Nasal polyps, deviated septum, or nasal/facial anatomic abnormalities that interfere with symptom evaluation and/or use of intranasal corticosteroids
- Treatment with more than 2 courses of systemic corticosteroids (each course not exceeding 14 days) within 1 year of screening
- Use of intranasal or ocular corticosteroids within 2 weeks of screening
- Use of oral, inhaled, or intravenous corticosteroids within 1 month of screening
- Use of intramuscular or intra-articular corticosteroids within 3 months of screening
- Use of high potency dermatological corticosteroids within 1 month of screening
- Use of oral leukotriene modifiers within 1 week of screening
- Use of nasal or oral antihistamines or oral or nasal decongestants within 3 days of screening
- Current or history of cataract or glaucoma
- Treatment with any investigational product or use of an investigational device within 1 month of screening
- Immunotherapy, with the exception of a stable maintenance schedule, for at least 1 month prior to screening
- History of hypersensitivity to glucocorticoids or to any excipients of the formulation
- Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof directly involved in the conduct of the protocol.
Any waiver of these inclusion and exclusion criteria must be approved by the investigator and the sponsor on a case-by-case basis prior to enrolling the subject. This must be documented by both the sponsor and the investigator.
No subject will be allowed to enroll in this study more than once.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Double-blind phase: Change from baseline in mean daily instantaneous (immediately prior to dosing) Total Nasal Symptom Score (TNSS) over the 4-week double-blind period
|
Open-label phase: The efficacy variable is the global evaluation of efficacy as rated by the physician and the subject
|
Secondary Outcome Measures
Outcome Measure |
---|
Change from baseline: in mean daily reflective (previous 24 hours) TNSS over 4-wk double-blind period
|
for mean daily instantaneous and reflective TNSS by week
|
for mean instantaneous and reflective daily scores for nasal stuffiness, nasal discharge, sneezing, nasal itching, and total eye symptoms by week and over four week double-blind period
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Phyllis Diener, BS, MT (ASCP), Sanofi
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Perennial
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Triamcinolone
Other Study ID Numbers
- XRG5029C_3502
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhinitis, Allergic, Perennial
-
UCB PharmaCompletedRhinitis | Allergic | Perennial
-
United Allergy ServicesCompletedPerennial Allergic Rhinitis With Seasonal VariationUnited States
-
Eli Lilly and CompanyNot yet recruitingPerennial Allergic Rhinitis (PAR)United States
-
Teva Branded Pharmaceutical Products R&D, Inc.United BioSource, LLCCompletedEffectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis (BALANCE)Perennial Allergic Rhinitis (PAR)United States
-
UCB PharmaCompletedRhinitis | Allergic | Perennial
-
SanofiCompleted
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AVRecruitingPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis | Local Allergic RhinitisBelgium
-
ALK-Abelló A/SCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
Clinical Trials on Triamcinolone
-
Peking University Third HospitalActive, not recruitingOsteoarthritis, KneeChina
-
Hospital de BragaUniversity of MinhoUnknown
-
Jaeb Center for Health ResearchNational Eye Institute (NEI)CompletedDiabetic Macular Edema
-
University of California, San FranciscoGenentech, Inc.Terminated
-
Montefiore Medical CenterTerminatedHidradenitis SuppurativaUnited States
-
Wuhan UniversityRecruitingRefractory Granulomatous Lobular MastitisChina
-
Shin Kong Wu Ho-Su Memorial HospitalNational Science Council, TaiwanCompletedSubacromial Impingement Syndrome | Rehabilitation | Physical Therapy | Subacromial Bursitis | Therapeutic ExerciseTaiwan
-
Weill Medical College of Cornell UniversityCompletedNail Diseases | Nail PsoriasisUnited States
-
Clearside Biomedical, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate Uveitis | Noninfectious UveitisUnited States
-
Shahid Beheshti University of Medical SciencesCompletedDiabetic Macular EdemaIran, Islamic Republic of